A phase 1 randomised clinical trial of a novel Nipah virus vaccine, led by US researchers, may soon pave the way to prevent the deadly infection. 

All three doses and regimens of the vaccine named HeV-sG-V demonstrated to be safe and generated an immune response, according to the researchers in the study published in the journal The Lancet.